- A Phase 3 study on the efficacy and safety of Epirus' BOW015 rheumatoid arthritis drug relative to the currently-available Remicade "met its pre-specified statistical endpoint," and found "no meaningful differences observed in safety or immunogenicity."
- Results from the open label testing phase, including "one year immunogenicity, one year safety, and long-term responder rates," are expected in Q3.
- Epirus merger partner Zalicus (ZLCS) is responding quite well to the news.
Presentations and Quarterly Reports - Research Report on NPS, Zalicus, Charles River, Insulet, and Sagent
at CNBC.com (Nov 14, 2013)